50th week of 2014 patent applcation highlights part 45 |
Patent application number | Title | Published |
20140364324 | NANOPORE SEQUENCING USING CHARGE BLOCKADE LABELS - The invention relates to devices and methods for nanopore sequencing. The invention includes compositions and methods of nucleic acid sequencing using a single polymerase enzyme complex comprising a polymerase enzyme and a template nucleic acid attached proximal to a nanopore, and nucleotide analogs in solution comprising charge blockade label that are attached to the polyphosphate portion of the nucleotide analog such that the charge blockade labels are cleaved when the nucleotide analog is incorporated into a growing nucleic acid and the charge blockade label is detected by the nanopore to determine the presence and identity of the incorporated nucleotide and thereby determine the sequence of a template nucleic acid. | 2014-12-11 |
20140364325 | Array of Sensors Functionalized with Systematically Varying Receptor Materials - A sensor array includes resonator sensors having respective receptor materials disposed thereon. The receptor materials have a physical property relevant to their ability to bind or adsorb one or more analytes in a sample. The physical property of the receptor materials on the sensors systematically increases or decreases in degree from one sensor to the next in the array. The device also comprises at least one detector for detecting sensor responses when masses of the analytes are adsorbed or bound to the receptor materials on the sensors. With this graded panel of sensors in the array, the analytes may adsorb or bind to the functionalized sensors with a pattern of responses specific to each analyte. | 2014-12-11 |
20140364326 | COMBINATORIAL BIOMARKERS FOR CLINICAL APPLICATIONS IN LUNG CANCER PATIENT MANAGEMENT - The present invention relates to compositions and methods for detecting, managing or monitoring cancer. The invention also relates to antibodies specific for cancer markers, compositions and chips containing the same, as well as their uses for cancer detection, managing, monitoring, imaging or treatment, as well as for drug development. The invention is particularly suited for detecting, managing or monitoring lung cancer in human subjects. | 2014-12-11 |
20140364327 | Compositions and Methods for the Systemic Treatment of Arthritis - The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β. | 2014-12-11 |
20140364328 | Diagnostic Biomarker Profiles for the Detection and Diagnosis of Parkinsons Disease - The present invention provides methods, compositions and kits for the detection of Parkinson' disease (PD) diagnostic biomarkers, for the diagnosis of PD, for the identification of a subject at risk for developing PD, and for the generation of patient-specific PD diagnostic biomarker profiles. | 2014-12-11 |
20140364329 | METHODS FOR IDENTIFYING PROTEIN-PROTEIN INTERACTIONS - The invention generally relates to methods for identifying protein-protein interactions. In certain aspects, methods of the invention involve conducting a protein-fragment complementation assay on a sample to form a protein-protein complex between two proteins in the sample that only transiently interact under physiological conditions, separating the complexes from the sample, and analyzing a protein of the complex using a mass spectrometry technique. | 2014-12-11 |
20140364330 | Multiplexed Olfactory Receptor-Based Microsurface Plasmon Polariton Detector - The invention provides a bio-sensing nanodevice comprising: a stabilized G-protein coupled receptor on a support, a real time receptor-ligand binding detection method, a test composition delivery system and a test composition recognition program. The G-protein coupled receptor can be stabilized using surfactant peptide. The nanodevice provides a greater surface area for better precision and sensitivity to odorant detection. The invention further provides a microfluidic chip containing a stabilized G-protein coupled receptor immobilized on a support, and arranged in at least two dimensional microarray system. The invention also provides a method of delivering odorant comprising the step of manipulating the bubbles in complex microfluidic networks wherein the bubbles travel in a microfluidic channel carrying a variety of gas samples to a precise location on a chip. The invention further provides method of fabricating hOR17-4 olfactory receptor. | 2014-12-11 |
20140364331 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for prostate cancer. | 2014-12-11 |
20140364332 | PEPTIDES AND METHODS FOR THE DETECTION OF LYME DISEASE ANTIBODIES - The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to | 2014-12-11 |
20140364333 | Methods for Live Imaging of Cells - The present invention relates to methods of hybridizing nucleic acid probes to genomic DNA. | 2014-12-11 |
20140364334 | CONGESTIVE HEART FAILURE BIOMARKERS - The invention provides gene and protein markers for cardiac disease and methods for using them to identify patients at risk for developing heart failure, or patients in an early stage of heart failure whose disease is likely to advance to a later stage. The present invention allows a treatment provider to identify those patients whose disease is most likely to develop and/or advance, and to initiate and/or adjust treatment options for such patients accordingly. | 2014-12-11 |
20140364335 | METHOD FOR SCREENING FOR NRF1 REGULATOR - The present invention provides a method for screening a test compound for a compound regulating Nrf1 activity, comprising using Nrf1 and Lipin1 and/or PGC-1β. A method for screening for a compound regulating Nrf1 activity is provided by the invention. | 2014-12-11 |
20140364336 | TRANSCRIPTION BIOMARKERS OF BIOLOGICAL RESPONSES AND METHODS OF USE - This invention provides transcription regulatory control sequences, the activity of which function as biomarkers for a variety of biological responses. This invention also provides expression constructs in which a biomarker transcription regulatory sequence is operably linked with a sequence for a reporter. Cells that comprise these expression constructs can be used in assays to identify conditions that modulate activity of the biological response. | 2014-12-11 |
20140364337 | ABSOLUTE QUANTITATION OF PROTEINS AND PROTEIN MODIFICATIONS BY MASS SPECTROMETRY WITH MULTIPLEXED INTERNAL STANDARDS - A method for absolute protein or peptide quantitation by mass spectroscopy. A sample containing a protein or peptide of interest is prepared for mass spectroscopy analysis. The sample is subjected to mass spectroscopy analysis at low resolution whereby a single additive mass spectroscopy peak is obtained, then is subjected to high resolution mass spectroscopy analysis whereby a plurality of mass spectroscopy peaks are obtained. The intensity of each of the plurality of mass spectroscopy peaks is quantitated either by comparison to an internal standard set, or by using a standard curve generated for each isotopologue set. Quantitation using a standard curve enhances quantitation across a dynamic range of analyte. | 2014-12-11 |
20140364338 | Adeno-Associated Virus Virions with Variant Capsid and Methods of Use Thereof - The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease. | 2014-12-11 |
20140364339 | VERSATILE AND STEREOSPECIFIC SYNTHESIS OF GAMMA,DELTA -UNSATURATED AMINO ACIDS BY WITTIG REACTION - The γ,δ-unsaturated α-amino acids of general formula (I). Also, a versatile process for the stereospecific synthesis of said compounds of formula (I), involving a Wittig reaction. Further, intermediate products of general formulae (II) and (III), as shown below, which are involved in the synthesis of compounds (I). | 2014-12-11 |
20140364340 | RATIONALLY DESIGNED, SYNTHETIC ANTIBODY LIBRARIES AND USES THEREFOR - The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system and are based on rational design informed by examination of publicly available databases of human antibody sequences. | 2014-12-11 |
20140364341 | PREDICTIVE MARKERS AND BIOMARKERS FOR OVARIAN CANCER - Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided. | 2014-12-11 |
20140364342 | MICROARRAY PROCESSING APPARATUS, WELL PLATE FOR MICROARRAY PROCESSING APPARATUS, MICROARRAY HOLDER, AND MICROARRAY WASHING METHOD - Provided is a microarray processing apparatus which is capable of sufficiently washing a microarray. The microarray processing apparatus ( | 2014-12-11 |
20140364343 | Produced Water Borate Crosslinking Compositions and Method of Use - A composition and method for treating a fracturing fluid comprising produced water with high levels of dissolved solids using a polymer crosslinked with a boron compound and a high pH alkylamine buffer. The composition improves the viscosity stability of the fracturing fluid at elevated bottom-hole temperatures, particularly when the fluid has high levels of calcium and magnesium. The composition is particularly useful with polysaccharides, including galactomannan gums, such as guar gum, locust bean gum, and karaya gum, and allows for the use of the preferred boron compound crosslinkers in high total dissolved solids fracturing fluids without the pH destabilization problems encountered with the prior art. | 2014-12-11 |
20140364344 | HYDRATION SYSTEM AND METHOD THEREOF - A hydration system configured to selectively enable a continuous process or a batch process of an additive for a hydraulic fracturing fluid, the hydration system including a hydration tank having a plurality of compartments, wherein the hydration tank is configured to enable movement of a material through the plurality of compartments in the continuous process. The hydration tank is configured to substantially restrict movement of the material between the plurality of compartments in the batch process. Also included is a method of selectively hydrating an additive in a batch process or a continuous process using a hydration system configured to enable both the batch process and the continuous process, | 2014-12-11 |
20140364345 | Compositions, Systems and Methods of Making Coated Additive Components - Compositions, systems and methods for the prevention or reduction of clumping or sticking of particulate hydraulic fracturing chemical additives. In preferred examples the particulate hydraulic fracturing chemical additives may be coated with, for example, a coating comprising a polymeric component and with or without silica. Inorganic flow agents (IFA) may be applied to the exterior surface of the particulate hydraulic fracturing chemical additives to prevent hardening or clumping of the additives upon storage. Preferably the coating is permeable, but insoluble in an aqueous medium, whereupon the additive components are released into the medium. | 2014-12-11 |
20140364346 | VISCOUS FLUID DILUTION SYSTEM AND METHOD THEREOF - A dilution system for a hydraulic fracturing fluid, the dilution system including a dilution manifold; a hydration unit configured to provide a source of liquid; a diluent line connecting the hydration unit to the dilution manifold. A diluent flow control valve on the diluent line. A hydration tank configured to hydrate a mixed additive. A gravity-driven viscous fluid line connecting an exit of the hydration tank to the dilution manifold. A viscous fluid flow meter on the viscous fluid line; and, a viscous fluid control valve on the viscous fluid line. Also included is a method of processing a fracturing fluid. | 2014-12-11 |
20140364347 | DI-FUNCTIONAL ANIONIC SURFACTANTS FOR ENHANCED OIL RECOVERY - The present invention describes the synthesis and use of cleavable di-functional anionic surfactants for enhanced oil recovery applications and/or the use of sacrificial surfactants. | 2014-12-11 |
20140364348 | Nano-Tribology Compositions and Related Methods Including Hard Particles - Compositions having a plurality of hard particles and a plurality of lubricant nanoparticles are disclosed. Methods of making and using the compositions are also disclosed. | 2014-12-11 |
20140364349 | MIXTURES OF OLEFIN-ESTER COPOLYMER WITH POLYOLEFIN AS VISCOSITY MODIFIER - A lubricant composition of an oil of lubricating viscosity; an esterified copolymer with a backbone comprising units derived from (i) an α-olefin monomer of at least about 6 carbon atoms and (ii) an ethylenically unsaturated carboxylic acid in a mole ratio of 1:3 to 3:1; and a polymer comprising olefin monomer units of 3 to 5 carbon atoms, wherein at least 50 percent by weight of such units contain fewer than 6 carbon atoms and wherein less than 5 percent by weight of such units are ethylene monomer units; exhibits good power transfer efficiency and elastohydrodynamic film thickness. | 2014-12-11 |
20140364350 | LUBRICATING OIL COMPOSITION - A lubricating oil composition contains: a first base oil with a kinematic viscosity at 100 degrees C. in a range from 1.5 mm | 2014-12-11 |
20140364351 | Process for preparing a mixture of alcohols - A method for preparing a mixture (M) including at least one alcohol (Aj), wherein said method includes a gas-phase oligomerization reaction of at least one alcohol (Ai) with a solid acid-base catalyst doped with one or more metals, said reaction being carried out in the presence of hydrogen and at a temperature of no less than 50° C. and strictly less than 200° C. | 2014-12-11 |
20140364352 | Material Release System - A material encapsulation and release system having a first zone ( | 2014-12-11 |
20140364353 | DETERGENT COMPOSITION - Detergent compositions are described having more than one enzyme, in particular having a multi-enzyme co-particle as well as methods of making and using such detergents. The compositions also have low levels of zeolite and phosphate builders and a moisture sink to minimize interaction between enzymes. | 2014-12-11 |
20140364354 | WATER-BASED DETERGENT - An aqueous detergent contains: (A) a branched carboxylic acid having 9 to 11 carbon atoms; (B) alkanolamine; and (C) at least one of phosphate represented by a formula [1] below or a salt of the phosphate, | 2014-12-11 |
20140364355 | LINEAR ALKYLBENZENES FROM NATURAL OILS AND METHODS OF PRODUCING - A linear alkyl benzene product and production of linear alkylbenzene from a natural oil are provided. A method comprises the step of deoxygenating the natural oils to form a stream comprising paraffins. The paraffins are dehydrogenated to provide mono-olefins. Then, benzene is alkylated with the mono-olefins under alkylation conditions to provide an alkylation effluent comprising alkylbenzenes and benzene. Thereafter, the alkylbenzenes are isolated to provide the alkylbenzene product. | 2014-12-11 |
20140364356 | FABRIC CARE COMPOSITIONS - The present invention is directed to fluid fabric enhancing compositions and processes of making and using same. Such fluid fabric enhancing compositions have a desirable fabric enhancer active efficiency that is, at least in part, due to the particle index of such fluid fabric enhancing compositions. Certain chemical processing and physical processing methods are not required to produce such compositions. | 2014-12-11 |
20140364357 | Fragrance Composition - A fragrance composition is described which comprises: at least two different fragrance accords wherein at least 30 wt % of each fragrance accord comprises the key contributor(s) of said fragrance accord and wherein the average of the odour detection thresholds of said key contributor(s) for each fragrance accord is within the same order of magnitude as the average of the odour detection thresholds of the key contributor(s) for said other fragrance accord(s); and wherein the base note(s) of each fragrance accord comprises less than 15% of the notes of said accord. Methods of manufacture thereof together with methods of attenuating fragrance habituation are also described. | 2014-12-11 |
20140364358 | Method for Preventing and Treating Hyperpermeability - A peptide is described, which consists of 7-17 adjacent amino acids and comprises the hexamer TXEXXE, wherein X, X and X can be any natural or non-natural amino acid, wherein the peptide has no TNF receptor binding activity and is cyclized, for the prevention and treatment of hyperpermeability of epithelial cells and endothelial cells. | 2014-12-11 |
20140364359 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND INFLAMMATION-RELATED DIESEASES AND CONDITIONS - The invention provides di-peptide conjugated antitumor agents, pharmaceutical compositions and methods for preparation and use thereof for treating various cancer and inflammation-related diseases and conditions. The present invention addresses the shortcomings of the existing anti-tumor and anti-inflammatory drugs, particularly in that the anti-tumor agents of the invention that selectively kill cancer cells with minimal damage to normal cells. Similarly, the anti-inflammatory agents of the invention provide effective treatment of various inflammatory diseases and conditions without the many deleterious side effects commonly associated with steroids | 2014-12-11 |
20140364360 | GLYCOSAMINOGLYCANS FOR CHEMOKINE DRUG DELIVERY - A pharmaceutical composition for sustained release of a chemokine is described that includes a polymer bonded to a sulfated glycosaminoglycan and loaded with a chemokine having affinity for the sulfated glycosaminoglycan. The pharmaceutical composition can be used in a method for providing sustained release of a chemokine to subject by contacting the subject with the pharmaceutical composition. | 2014-12-11 |
20140364361 | HIGH PROTEIN LIQUID ENTERAL NUTRITIONAL COMPOSITION - The present invention relates in general to a shelf-stable liquid enteral composition for providing nutrition, either as a supplement, or as a complete nutrition, with a high protein content of a non-hydrolysed globular protein, in particular a whey protein. | 2014-12-11 |
20140364362 | THERAPEUTIC AGENTS COMPRISING INSULIN AMINO ACID SEQUENCES - The present invention relates in part to agents which provide slow absorption from an injection site. In some embodiments, the pharmaceutical compositions comprises an insulin amino acid sequence and an amino acid sequence that provide slow absorption from an injection site, such as, for example, an amino acid sequence that has a substantially repeating pattern of proline residues. | 2014-12-11 |
20140364363 | GLYPICAN-4 BASED COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING INSULIN RESISTANCE - Provided herein are methods for increasing insulin sensitivity in a subject. A method may comprise administering to a subject in need of increased insulin sensitivity a therapeutically effective amount of a glypican-4 agent. Also provided herein are methods for determining whether a subject is or is likely to become insulin resistant. A method may comprise determining the level of glypican-4 in a subject, wherein an elevated level of glypican-4 indicates that a subject is or is likely to become insulin resistant. | 2014-12-11 |
20140364364 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS - The present invention provides methods for treating and/or preventing mucostitis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same. | 2014-12-11 |
20140364365 | Mask for Skin Care - A mask for skin care includes a fiber substrate, wherein the fiber substrate is woven or nonwoven, and includes modified fibers, and the modified fibers are cellulose fibers with at least one hydrophilic functional group grafted on. The grafted ratio of the modified fibers is in the range from 5% to 30%, and the modified fibers can effectively improve the moisture absorption and the moisture-retaining capacity of the mask for skin care. | 2014-12-11 |
20140364366 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE - The present invention provides methods for treating chronic heart failure patients using the medication comprising neuregulin. The methods comprise first performing a companion diagnostic test of each patient before treatment; and then providing a suitable treatment to the patient according to the results of the companion diagnostic test. When the result of the test is within a favorite treatment zone, the patient is suitable for heart failure treatment by administering an effective amount of neuregulin. | 2014-12-11 |
20140364367 | METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER - This invention relates to treating Prader-Willi Syndrome (PWS) using a KATP channel opener. The channel opener may be coadministered with other therapies used to treat PWS, such as human growth hormone, a wakefulness promoting agent, or a psychiatric or mood stabilizing drug, thereby allowing the baseline dosages of these other therapies to be decreased or making these other therapies unnecessary. The invention also relates to treating PWS based on the PWS nutritional phase of a patient, to prevent the patient's PWS nutritional phase from progressing or shift the patient's PWS nutritional phase back to an earlier phase. The invention further relates to treating PWS, and conditions associated with low basal metabolic rate or hyperphagia, with the KATP channel opener based on a patient's blood ketone levels. | 2014-12-11 |
20140364368 | STIMULUS RESPONSIVE NANOCOMPLEXES AND METHODS OF USE THEREOF - The present invention provides stimulus responsive nanocomplexes comprising a masking moiety, e.g., a peptide, and a therapeutic moiety, e.g., an anti-coagulant. The invention also provides methods for treating or preventing a condition, such as a hypercoagulable state, e.g., blood clotting disorders or a cardiovascular disease, in a subject. | 2014-12-11 |
20140364369 | USE OF CHEMICALLY MODIFIED HEPARIN DERIVATES IN SICKLE CELL DISEASE - The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. | 2014-12-11 |
20140364370 | COMBINATION THERAPIES USING CYCLOSPORINE AND AROMATIC CATIONIC PEPTIDES - The invention provides compositions and methods for preventing or treating an ischemia-reperfusion injury, such as occurs during acute myocardial infarction and organ transplant in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide or a pharmaceutically acceptable salt thereof, and one or more additional active agents such as cyclosporine. | 2014-12-11 |
20140364371 | DIRECT DRUG DELIVERY SYSTEM BASED ON THERMALLY RESPONSIVE BIOPOLYMERS - A method for delivering a drug depot of a compound of interest to a selected region in a subject. The method comprises administering a composition directly to said region of interest, the composition comprising the compound of interest to be delivered (such as an antiinflammatory agent or a chemotherapeutic agent) and a polymer (such as an elastin-like peptide or ELP) that undergoes an inverse temperature phase transition, so that a sustained release of the compound of interest at the selected region is provided. Compositions useful for carrying out the invention are also described. | 2014-12-11 |
20140364372 | REGENERATION AND REPAIR OF MESENCHYMAL TISSUE USING AMELOGENIN - A method of treating an injury to hyaline cartilage in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of amelogenin. | 2014-12-11 |
20140364373 | NOVEL ENTERIC COMBINATION THERAPY - There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers' diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-Clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-Clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers' diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neurone Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-Clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-Clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment. | 2014-12-11 |
20140364374 | AMINO ACID SEQUENCE FOR INHIBITING PTX3 TO TREAT NASOPHARYNGEAL CARCINOMA - The invention relates to an amino acid sequence for inhibiting PTX3 to treat nasopharyngeal carcinoma. It can be used to inhibit PTX3 from promoting the migration and invasion of nasopharyngeal carcinoma cells, promoting angiogenesis and inhibiting macrophage phagocytosis to further treat nasopharyngeal carcinoma. | 2014-12-11 |
20140364375 | Combination Therapy with Peptide Epoxyketones - The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent. | 2014-12-11 |
20140364376 | CELL-PENETRATING PEPTIDES - The invention relates to a cell-penetrating peptide, optionally linked to a pro-apoptotic peptide, useful as pro-apoptotic agents, for inhibition of in vitro cell proliferation and for treatment of tumors. | 2014-12-11 |
20140364377 | USE OF PEPTIDE EPOXYKETONES FOR METASTASIS SUPPRESSION - The invention provides a method of repressing metastasis of a cancer compromising the administration of a peptide epoxyketone proteasome inhibitor. Furthermore, the method can be performed in combination with the administration of one or more additional therapeutics. | 2014-12-11 |
20140364378 | METHOD AND PHARMACEUTICAL COMPOSITION FOR HAIR GROWTH - The present disclosure relates to a method and a pharmaceutical composition for hair growth. The pharmaceutical composition includes a hair growth peptide (HGP) which includes all or part of the amino acid sequence SEQ ID No: 1. The method includes administering a hair growth peptide (HGP) which includes all or part of the amino acid sequence SEQ ID No: 1 to an interest. | 2014-12-11 |
20140364379 | TWO PART FORMULATION SYSTEM FOR OPHTHALMIC DELIVERY - Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent. | 2014-12-11 |
20140364380 | LIPOPEPTIDE COMPOSITIONS AND RELATED METHODS - The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose. | 2014-12-11 |
20140364381 | WOUND DRESSINGS WITH ENHANCED GAS PERMEATION AND OTHER BENEFICIAL PROPERTIES - A wound dressing comprises a wound dressing substrate including one or more of gas vesicles, rhamnolipids, and sophorolipids. The wound dressing can be fabric-based or hydrogel-based. Methods for producing a wound dressing are also provided. | 2014-12-11 |
20140364382 | COMPOSITION FOR INHIBITING LIVER FUNCTION DETERIORATION, CONTAINING CITRUS PEEL EXTRACT OR NARIRUTIN AS ACTIVE INGREDIENT, AND METHOD FOR EXTRACTING NARIRUTIN FROM CITRUS PEEL - The present invention relates to a pharmaceutical composition for treating liver diseases, containing a narirutin extract of citrus peel extract or narirutin as an active ingredient. The extract or narirutin decreases cholesterol levels and fat levels in liver tissue, and thus can be utilized as a composition or food for preventing and treating liver diseases. In addition, the present invention relates to a method for extracting narirutin from citrus peel, and a method for preparing citrus fermented milk using the same. | 2014-12-11 |
20140364383 | METHODS AND COMPOSITIONS FOR APPLYING PHARMACOLOGIC AGENTS TO THE EAR - Methods and materials useful for applying pharmacologic agents to the ear are described. The methods involve delivering a composition that contains at least one viscogenic agent and at least one pharmacologic agent to the epidermal surface of the tympanic membrane via the ear canal. The composition is delivered to the tympanic membrane in a flowable form and, after delivery to the tympanic membrane, becomes sufficiently viscous such that the pharmacologic agent is localized against the tympanic membrane. Such compositions can be used to prophylactically and/or therapeutically treat middle and inner ear conditions, including otitis media. | 2014-12-11 |
20140364384 | MEDICATION ADHERENCE MONITORING SYSTEM - The present invention relates to the detection of markers in exhaled breath, wherein the detection of the presence or absence of the marker(s) in exhaled breath is used to assess various clinical data, including patient adherence in taking the medication and patient enzymatic (metabolic) competence in metabolizing the medication. An embodiment of the invention comprises a parent therapeutic agent labeled with a marker, where upon metabolism (e.g., via enzymatic action) of the therapeutic agent, the marker becomes volatile or semi-volatile and is present in the breath. In certain related embodiments, the marker contain a deuterium label, which is also present in the breath upon metabolism of the therapeutic agent. In another embodiment of the invention, the therapeutic agent is associated with a taggant (that may be either labeled or unlabeled with deuterium), which in turn will generate a marker in the breath that is easily measurable. | 2014-12-11 |
20140364385 | FORAZOLINES, COMPOSITIONS THEREOF AND USES THEREOF - An isolated compound of Formula I and salts thereof are provided: | 2014-12-11 |
20140364386 | Small Molecule Compounds That Control Plant- and Insect-Pathogenic Nematodes - The present invention relates to methods of modifying nematode behavior using certain isolated modulator compounds. Also disclosed are methods of promoting or inhibiting reproduction in a nematode population, methods of promoting or inhibiting nematode aggregation at a first location, and methods of treating or preventing parasite infection of a plant. | 2014-12-11 |
20140364387 | METHODS AND SYSTEMS FOR MODULATING HORMONES AND RELATED METHODS, AGENTS AND COMPOSITIONS - Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual. | 2014-12-11 |
20140364388 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF - The present application provides methods and compositions for inducing hepatocyte proliferation and liver regeneration, the latter being mainly dependent on hepatocyte proliferation even if all the other cell types divide to reconstitute the organ specific-lobular-architecture. The methods and compositions provided herein make use of an A | 2014-12-11 |
20140364389 | Combination Therapy - The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (“Compound A”) or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans. | 2014-12-11 |
20140364390 | XYLOGLUCAN-BASED COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS - Described herein are compositions including xyloglucans as an active ingredient useful in the treatment of gastro-intestinal disorders or of disorders originating from the gastro-intestinal system and transferred to other systems, such as the genitourinary system. The compositions may have xyloglucans or an extract containing xyloglucans, and may further include other active ingredients. | 2014-12-11 |
20140364391 | Immobilization Of An Active Agent On A Substrate Using Compounds Including Trihydroxyphenyl Groups - The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, providing a substrate, contacting the substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated substrate, and contacting the trihydroxyphenyl-treated substrate with an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof. | 2014-12-11 |
20140364392 | TOPICAL AQUEOUS OPHTHALMIC COMPOSITIONS CONTAINING A 1H-INDOLE-1-CARBOXAMIDE DERIVATIVE AND USE THEREOF FOR TREATMENT OF OPHTHALMIC DISEASE - The present invention is directed to the provision of a multi-dose topical ophthalmic composition containing a 1H-indole-1-carboxamide and use thereof for treatment of ophthalmic disease. More specifically the present invention is directed to a multi-dose aqueous ophthalmic composition (e.g., a solution, a suspension, an emulsion or the like) containing a 1H-indole-1-carboxamide (e.g., N-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino) methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide) and use thereof for treatment of an ophthalmic disease at the back of the eye such as age related macular degeneration (AMD). | 2014-12-11 |
20140364393 | SUBSTITUTED PIPERIDINYL-CARBOXAMIDE DERIVATIVES USEFUL AS SCD 1 INHIBITORS - The present invention is directed to novel piperidinyl-carboxamide derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders. | 2014-12-11 |
20140364394 | Novel Liquid Organopolysiloxane And Uses Thereof - A liquid organopolysiloxane having fluidity at least 100° C., a silicon-bonded glycerin derivative group, and a crosslinked structure comprising a carbon-silicon bond at the crosslinking portion. | 2014-12-11 |
20140364395 | Pyranyl Aryl Methyl Benzoquinolinone M1 Receptor Positive Allosteric Modulators - The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) | 2014-12-11 |
20140364396 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors - The present invention provides compounds of Formula (I) as inhibitors of LMP7 for the treatment of autoimmune and inflammatory diseases. | 2014-12-11 |
20140364397 | ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS - The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer. | 2014-12-11 |
20140364398 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents - The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections. | 2014-12-11 |
20140364399 | PHOSPHOLIPID COMPOSITIONS ENRICHED FOR PALMITOLEIC, MYRISTOLEIC OR LAUROLEIC ACID, THEIR PREPARATION AND THEIR USE IN TREATING METABOLIC AND CARDIOVASCULAR DISEASE - The present invention concerns phospholipid compositions having a relatively high concentration of compounds of the following structure (I): wherein at least one of R | 2014-12-11 |
20140364400 | ESTERS FOR TREATMENT OF OCULAR INFLAMMATORY CONDITIONS - The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens. | 2014-12-11 |
20140364401 | ANTISPASMODIC 1,2-DIOLS AND 1,2,3-TRIOLS - The present invention is directed to pharmaceutical compositions comprising antispasmodic C | 2014-12-11 |
20140364402 | ASSAY FOR SCREENING COMPOUNDS THAT SELECTIVELY DECREASE THE NUMBER OF CANCER STEM CELLS - The present invention provides, inter alia, a method for identifying an agent that selectively decreases the number of cancer stem cells (CSCs). This method includes (a) contacting a CSC from a population of cells with a candidate agent; and (b) determining whether the candidate agent reduces the survival or growth of the CSC or increases differentiation of the CSC relative to a CSC that has not been contacted with the candidate agent. The method may be used as a high throughput screen. | 2014-12-11 |
20140364403 | Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders - Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 2014-12-11 |
20140364404 | ARTICLES AND METHODS OF TREATING VASCULAR CONDITIONS - The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site. | 2014-12-11 |
20140364405 | TREATMENT OF SEBORRHOEA - A method for the treatment of seborrhoea in a patient comprises administering to the patient an effective amount of (24RS) or (24S) scymnol, an ester thereof or a pharmaceutically acceptable salt of a said ester, or of (24R) scymnol. | 2014-12-11 |
20140364406 | Method Of Treating Or Preventing Pathologic Effects Of Acute Increases In Hyperglycemia And/Or Acute Increases Of Free Fatty Acid Flux - One aspect of the present invention relates to a method of treating or preventing pathologic sequelae of acute hyperglycemia and/or increased fatty acid flux in a subject. This method involves administering an ROS inhibitor to the subject. In addition, methods of promoting neovascularization, inhibiting oxidation or excessive release of free fatty acids, and identifying compounds suitable for treatment or prevention of ROS-mediated injury are also disclosed. | 2014-12-11 |
20140364407 | MEDICAL OR THERAPEUTIC APPLICATION OF A COMPOSITE MATERIAL OF RUTHENIUM WITH A NITROSYL LIGAND - A medical or therapeutic application of a composite material of ruthenium with a nitrosyl ligand. Application for a medical or therapeutic treatment of a composite material of ruthenium with a nitrosyl ligand irradiated in a spectral range capable of releasing the nitrosyl ligand, i.e., the ultraviolet or visible or near-infrared spectral range. | 2014-12-11 |
20140364408 | Hydrazide Containing Nuclear Transport Modulators And Uses Thereof - The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity. | 2014-12-11 |
20140364409 | SUBSTITUTED PYRAZOLO[3',4':4,5]THIENO[2,3-C]PYRIDAZIN-3-AMINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 - In one aspect, the invention relates to substituted pyrazolo[3′,4′:4,5]thieno[2,3-c]pyridazine-3-amine analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M | 2014-12-11 |
20140364410 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS - The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof. | 2014-12-11 |
20140364411 | KINASE INHIBITORS - Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract. | 2014-12-11 |
20140364412 | KINASE INHIBITORS - Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract | 2014-12-11 |
20140364413 | PDE 10a Inhibitors for the Treatment of Type II Diabetes - Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: | 2014-12-11 |
20140364414 | PDE 10a Inhibitors for the Treatment of Type II Diabetes - Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: | 2014-12-11 |
20140364415 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS - The present invention relates to compounds of Formula (I) | 2014-12-11 |
20140364416 | COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE - One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject. | 2014-12-11 |
20140364417 | METHOD OF TREATING ATRIAL FIBRILLATION - The present disclosure relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a therapeutically effective amount of ivabradine or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of ranolazine. Also provided are methods for modulating ventricular and atrial rate. This disclosure also relates to pharmaceutical formulations that are suitable for such combined administration. | 2014-12-11 |
20140364418 | COMPOSITIONS COMPRISING AN AROMATIC ALCOHOL AND A TRPV-1 ANTAGONIST, AND USES THEREOF - A topical composition providing reduced irritation that contains aromatic alcohols such as phenoxyethanol and a TRPV-1 antagonist is described. The composition is substantially free of parabens. The composition may be used for example for cleansing the skin. | 2014-12-11 |
20140364419 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA - Disclosed herein are methods for controlling the activity of hypoxia-inducible transcription factor 1-alpha (HIF-1α) and diseases, conditions, or syndromes related thereto, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. Further disclosed are pharmaceutical compositions comprising HIF-1α prolyl hydroxylase inhibitors useful in treating diseases, conditions, and/or syndromes related thereto the activity of HIF-1α. | 2014-12-11 |
20140364420 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS - The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: | 2014-12-11 |
20140364421 | BENZOTHIOPHENE COMPOUND - [Problem] A compound which is useful as an IK1 channel activator is provided. | 2014-12-11 |
20140364422 | Aqueous Pharmaceutical Composition With Enhanced Stability - The present invention is an aqueous pharmaceutical composition that includes an ionized therapeutic agent, an ionic component and guar gum. The guar gum is present in the composition a concentration sufficient to limit interactions between the ionized therapeutic agent and the ionic component thereby imparting stability to the composition. The composition is preferably at or near physiologic pH. The aqueous pharmaceutical composition has been found particularly useful as an aqueous ophthalmic, otic or nasal composition. The pharmaceutical composition, due to its characteristics, is particularly suitable as an ophthalmic composition. | 2014-12-11 |
20140364423 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors - This invention relates to compounds of the general formula: | 2014-12-11 |